滋肾润肺方辅助化疗治疗中晚期肺癌气阴两虚证患者的临床疗效

The Effect of Zishen Runfeifang in Combined with Chemotherapy on Clinical Efficacy with Advanced Lung Cancer Exhibiting Both Qi and Yin Deficiencies

【目的】探讨滋肾润肺方联合化疗治疗中晚期肺癌气阴两虚证患者的疗效。【方法】两院收治的80例中晚期肺癌气阴两虚证患者,随机分为化疗组与联合组,每组40例。化疗组采用常规肺癌化疗方案,联合组在此基础上同时给予滋肾润肺方口服。比较两组患者的疗效、疾病进展时间(TTP)、1年存活率、1年无进展生存(PFS)率,治疗前后中医症状积分、卡氏评分(KPS)改善情况,骨髓抑制发生情况。【结果】联合组治疗总有效率(RR)为37.5%(15/40)、疾病控制率(DCR)为82.5%(33/40),化疗组RR为27.5%(11/40)、DCR为70.0%(28/40),两组比较差异均无统计学意义(P>0.05)。化疗组TTP为6.5(4.2~8.4)个月,1年存活率为30.0%(12/40),1年PFS率为85.0%(34/40);联合组TTP为7.2(5.5~9.3)个月,1年存活率35.0%(14/40),1年PFS率为87.5%(35/40),两组比较差异均无统计学意义(P>0.05)。与治疗前比较,两组治疗后中医症状积分均明显降低,且观察组各项指标下降更显著(P<0.05)。治疗后,联合组KPS评分稳定率为90.00%(36/40),明显高于化疗组的70.00%(28/40)(P<0.05)。联合组骨髓抑制的总发生率为17.5%(7/40),低于化疗组的42.5%(17/40)(P<0.05)。【结论】滋肾润肺方联合化疗可有效改善患者的生活质量,且能降低骨髓抑制的发生率。

【Objective】To explore the efficacy of Zishen Runfeifang in combined with chemotherapy in patients with advanced lung cancer exhibiting both Qi and Yin deficiencies.【Methods】Eighty patients with advanced lung cancer exhibiting both Qi and Yin deficiencies,who received treatment in our two hospitals,were randomly divided into a chemotherapy group and a combination group,with 40 patients in each group.The chemotherapy group received conventional lung cancer chemotherapy,while the combination group received Zishen Runfeifang orally in addition to the chemotherapy.The efficacy,time to disease progression(TTP),1-year survival rate,1-year progression-free survival(PFS)rate,improvements in Traditional Chinese Medicine symptom scores,and Karnofsky Performance Scale(KPS)scores before and after treatment,as well as the occurrence of bone marrow suppression,were compared between the two groups.【Results】The total effective rate(RR)in the combination group was 37.5%(15/40)and the disease control rate(DCR)was 82.5%(33/40),whereas the chemotherapy group had an RR of 27.5%(11/40)and a DCR of 70.0%(28/40).The differences between the groups were not statistically significant(P>0.05).The TTP in the chemotherapy group was 6.5(4.2-8.4)months,with a 1-year survival rate of 30.0%(12/40),and a 1-year PFS rate of 85.0%(34/40);the combination group had a TTP of 7.2(5.5-9.3)months,a 1-year survival rate of 35.0%(14/40),and a 1-year PFS rate of 87.5%(35/40).The differences between the two groups were not statistically significant(P>0.05).Compared to before treatment,both groups showed a significant reduction in Traditional Chinese Medicine symptom scores after treatment,with more significant reductions in the combination group(P<0.05).After treatment,the stability rate of KPS scores in the combination group was 90.00%(36/40),significantly higher than the 70.00%(28/40)in the chemotherapy group(P<0.05).The total occurrence rate of bone marrow suppression in the combination group was 17.5%(7/40),lower than 42.5%(17/40)in the chemotherapy group.【Conclusion】Zishen Runfeifang combined with chemotherapy can effectively improve patients'quality of life and reduce the occurrence rate of bone marrow suppression.